Objective
Hepatitis B virus (HBV) chronic infection still poses a major health problem for Europe. The emergence of HBV variants will compound the problem if they are allowed to spread, leading to vaccine escape and chemotherapeutic failure. To prevent this, our collaborative study will: develop high throughput procedures for detecting these variants in patients from different parts of Europe; evaluate their immune escape and drug resistance phenotypes through the use of conventional and new cell culture and animal models; and establish quantification assays to monitor the dynamic of HBV variants during therapy. Our findings should lead to re-design of diagnostic assays, and of vaccine and therapeutic formulations, and to guidelines to biologists and clinicians for better prevention and treatment strategies. They should result in the reduction of HBV transmission and of severe liver disease in chronically infected patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis B
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicinehepatology
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
69424 LYON
France